It is important to mention that the current utilization of antibod-
ies, namely monoclonal antibodies (mAbs), for the treatment of dis-
eases incurs significant expenses, which are further complicated by
challenging production processes. Nevertheless, after their safety
and effectiveness have been verified, contemporary methods such
as genetic engineering and biotechnology exhibit promise in facili-
tating their extensive manufacturing. By employing these advanced
technologies, pharmaceutical companies can improve production
efficiency and achieve substantial cost savings related to antibody-
based therapies.